Get the Stockscreener App
1.43
0.70%
0.01
Pmv Pharmaceuticals Inc stock is traded at $1.43, with a volume of 45,036.
It is up +0.70% in the last 24 hours and up +5.93% over the past month.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
See More
Previous Close:
$1.42
Open:
$1.41
24h Volume:
45,036
Relative Volume:
0.27
Market Cap:
$73.48M
Revenue:
-
Net Income/Loss:
$-51.47M
P/E Ratio:
-1.43
EPS:
-1
Net Cash Flow:
$-47.50M
1W Performance:
+2.88%
1M Performance:
+5.93%
6M Performance:
-10.06%
1Y Performance:
-15.38%
1-Day Range:
$1.41
$1.43
1-Week Range:
$1.36
$1.465
52-Week Range:
$1.32
$2.26
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Name
Pmv Pharmaceuticals Inc
Sector
Industry
Phone
(609) 642-6664
Address
ONE RESEARCH WAY, PRINCETON
Compare PMVP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.43 | 73.48M | 0 | -51.47M | -47.50M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.15 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.27 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.71 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.07 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
117.11 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Upgrade | Oppenheimer | Perform → Outperform |
| May-13-24 | Initiated | Craig Hallum | Buy |
| Apr-12-24 | Initiated | Jefferies | Buy |
| Dec-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Mar-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-22-21 | Upgrade | Goldman | Neutral → Buy |
| Aug-19-21 | Initiated | Oppenheimer | Perform |
| Aug-02-21 | Initiated | Guggenheim | Buy |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Cowen | Outperform |
| Oct-20-20 | Initiated | Evercore ISI | Outperform |
| Oct-20-20 | Initiated | Goldman | Neutral |
View All
Pmv Pharmaceuticals Inc Stock (PMVP) Latest News
PMVP Stock Sees Surge of Approximately 2.86% in Last Five Days - Knox Daily
Catalio Capital Management Joins $15 Million Series A for Perceive Pharma - citybiz
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Sees Significant Drop in Short Interest - MarketBeat
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results - br.ADVFN.com
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences - GlobeNewswire
PMVP's Top Executives Set to Reveal Latest Oncology Developments at Major Healthcare Conferences - StockTitan
US Penny Stocks To Watch In January 2025 - Simply Wall St
Assenagon Asset Management S.A. Reduces Stock Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Barclays PLC Trims Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
Barclays PLC Trims Stock Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat
PMV Pharmaceuticals stock hits 52-week low at $1.32 By Investing.com - Investing.com Canada
PMV Pharmaceuticals stock hits 52-week low at $1.32 - MSN
Jane Street Group LLC Sells 89,957 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
Jane Street Group LLC Sells 18,128 Shares of New Found Gold Corp. (NYSE:NFGC) - Defense World
PMV Pharmaceuticals stock hits 52-week low at $1.4 amid market challenges - Investing.com India
PMV Pharmaceuticals stock hits 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa
Barclays PLC Sells 434,704 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
Barclays PLC Cuts Stock Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat
Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer - The Manila Times
PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials - GlobeNewswire
Layoff Tracker: Regeneron Acquisition of Oxular Wipes Out Oxular Workforce - BioSpace
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial - Nature.com
Institutional investors may overlook Premier Investments Limited's (ASX:PMV) recent AU$278m market cap drop as long-term gains remain positive - Yahoo Finance
When Should You Buy Premier Investments Limited (ASX:PMV)? - Yahoo Finance
Discover 3 US Penny Stocks With Market Caps Over $40M - Simply Wall St
ArrowMark Colorado Holdings LLC Purchases 842,509 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Given Average Rating of "Buy" by Brokerages - MarketBeat
Sio Capital Management LLC Boosts Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat
PMVP (PMV Pharmaceuticals) 6-Month Price Index : 0.78 (As of Nov. 28, 2024) - GuruFocus.com
PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer - MSN
Sionna Therapeutics Appoints Laurie Stelzer to its Board of Directors - citybiz
ArrowMark Colorado Holdings LLC Expands Stake in PMV Pharmaceuti - GuruFocus.com
BML Capital Management LLC Grows Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat
Icahn Enterprises Releases Third Quarter 2024 Financial Results - Defense World
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Receives $5.80 Average Target Price from Brokerages - MarketBeat
PMV Pharmaceuticals (NASDAQ:PMVP) Upgraded at Oppenheimer - MarketBeat
Oppenheimer raises PMVP rating to Outperform, sets stock target on Q3 results - Investing.com UK
PMV Pharmaceuticals Inc (PMVP) Quarterly 10-Q Report - Quartz
Karyopharm stock gains as late-stage trial changes (KPTI:NASDAQ) - Seeking Alpha
Rezatapopt Monotherapy Remains Under Study Following Discontinuation of Combination Cohort in TP53+ Solid Tumors - OncLive
Dr Cristofanilli on Applications for Liquid Biopsy–Based MRD Testing in Breast Cancer - OncLive
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines - Yahoo Finance
US Penny Stocks To Consider In October 2024 - Simply Wall St
PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial - GlobeNewswire
New Global Hematology Journal Strives to Feature Innovative and Adaptable Research - OncLive
Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Quotes, Forecast and News Summary - Benzinga
Pmv Pharmaceuticals Inc Stock (PMVP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pmv Pharmaceuticals Inc Stock (PMVP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mack David Henry | President and CEO |
Jan 03 '25 |
Option Exercise |
0.53 |
17,709 |
9,386 |
551,919 |
| Jalota Deepika | Chief Development Officer |
Sep 11 '24 |
Sale |
1.50 |
7,218 |
10,853 |
118,283 |
| Carulli Michael | Chief Financial Officer |
Sep 11 '24 |
Sale |
1.50 |
2,891 |
4,347 |
88,395 |
0.12%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):